Thompson Davis & CO. Inc. Makes New Investment in Augmedix, Inc. (NASDAQ:AUGX)

Thompson Davis & CO. Inc. purchased a new stake in Augmedix, Inc. (NASDAQ:AUGX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 20,500 shares of the company’s stock, valued at approximately $120,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of AUGX. Russell Investments Group Ltd. increased its position in shares of Augmedix by 292.0% during the fourth quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock valued at $5,213,000 after acquiring an additional 663,778 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in Augmedix in the 3rd quarter valued at approximately $2,237,000. Calamos Advisors LLC purchased a new stake in Augmedix in the fourth quarter valued at approximately $886,000. Taylor Frigon Capital Management LLC purchased a new stake in Augmedix in the third quarter valued at approximately $438,000. Finally, Perkins Capital Management Inc. raised its holdings in shares of Augmedix by 5.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,464,568 shares of the company’s stock valued at $8,568,000 after buying an additional 73,475 shares during the period. 87.11% of the stock is currently owned by hedge funds and other institutional investors.

Augmedix Stock Down 4.2 %

Augmedix stock traded down $0.12 during trading on Tuesday, reaching $2.71. The stock had a trading volume of 223,834 shares, compared to its average volume of 362,462. The company has a quick ratio of 2.41, a current ratio of 2.41 and a debt-to-equity ratio of 0.66. Augmedix, Inc. has a 52-week low of $2.61 and a 52-week high of $6.25. The business has a 50 day moving average price of $3.81 and a 200 day moving average price of $4.66.

Augmedix (NASDAQ:AUGX) last released its quarterly earnings data on Monday, March 18th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $12.68 million for the quarter, compared to analysts’ expectations of $12.30 million. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. On average, research analysts predict that Augmedix, Inc. will post -0.51 EPS for the current year.

Insider Transactions at Augmedix

In related news, insider Ian Shakil sold 31,994 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $4.06, for a total value of $129,895.64. Following the completion of the transaction, the insider now directly owns 187,666 shares of the company’s stock, valued at $761,923.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 251,323 shares of company stock valued at $1,005,527. Corporate insiders own 10.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. B. Riley began coverage on shares of Augmedix in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $5.50 price objective for the company. Maxim Group reduced their price objective on Augmedix from $6.50 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, March 19th. Finally, Evercore ISI raised Augmedix from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $4.50 to $5.00 in a research note on Tuesday, April 9th.

Augmedix Company Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.